Effects of bestatin on phagocytic cells in cyclophosphamide-treated mice

Pharmacological Reports

Volumn 63, Issue 6, 2011, Pages 1481-1490

  Lis, Magdalena ^a   Obmińska Mrukowicz, Bozena ^a  

^a WROCLAW UNIVERSITY OF ENVIRONMENTAL AND LIFE SCIENCES   (Poland)

Author keywords

Bestatin; Cyclophosphamide; IL 1 ; Mice; Oxidative burst; Phagocytosis

Indexed keywords

BESTATIN; CYCLOPHOSPHAMIDE; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL ACTIVITY; CELL COUNT; CELL FUNCTION; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; DRUG POTENCY; DRUG STRUCTURE; ENZYME RELEASE; ENZYME SYNTHESIS; ESCHERICHIA COLI; FEMALE; GRANULOCYTE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; MOLECULAR WEIGHT; MONOCYTE; MOUSE; NEUTROPHIL; NONHUMAN; OXIDATION; PERITONEUM MACROPHAGE; PHAGOCYTE; PROTEIN SECRETION; PROTEIN SYNTHESIS; SINGLE DRUG DOSE;

EID: 84857477738     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(11)70712-5     Document Type: Article

References (39)

1. Abe F, Matsuda A, Schneider M, Talmadge JE: Effects of bestatin on myelopoietic stem cells in normal and cyclophosphamide-treated mice. Cancer Immunol Immunother, 1990, 32, 75-80.
2. Aoyagi K, Itoh N, Abe F, Abe S, Uchida K, Ishizuka M, Takeuchi T, Yamaguchi H: Enhancement by ubenimex (bestatin) of host resistance to Candida albicans infection. J. Antibiot (Tokyo), 1992, 45, 1778-1784. (Pubitemid 23015459)
3. Bauvois B, Dauzonne D: Aminopeptidase-N/CD13 (EC 3.4.11.2.) Inhibitors: chemistry, biological evaluations and therapeutic prospects. Med Res Rev, 2006, 26, 88-130. (Pubitemid 43986471)
4. Bourinbaiar AS, Lee-Huang S, Krasinski K, Borkowsky W: Inhibitory effect of the oral immune response modifier, bestatin, on cell-mediated and cell-free HIV infection in vitro. Biomed Pharmacother, 1994, 48, 55-61. (Pubitemid 24113550)
5. Bryniarski K, Szczepanik M, Ptak M, Zemelka M, Ptak W: Influence of cyclophosphamide and its metabolic products on the activity of peritoneal macrophages in mice. Pharmacol Rep, 2009, 61, 550-557.
6. Chełmońska-Soyta A, Miller RB, Ruhnke L, Rosendal S: Activation of murine macrophages and lymphocytes by Ureaplasma diversum. Can J Vet Res, 1994, 58, 275-280.
7. Ezawa K, Minato K, Dobashi K: Induction of apoptosis by ubenimex (Bestatin) in human non-small-cell lung cancer cell lines. Biomed Pharmacother, 1996, 50, 283-289. (Pubitemid 26330287)
8. Fujisaki T, Otsuka T, Takamatsu Y, Eto T, Harada M, Niho Y: Effects of bestatin on hematopoiesis in longterm human bone marrow cultures. Biomed Pharmacother, 1995, 49, 69-74.
9. Harada Y, Kajiki A, Higuchi K, Ishibashi T, Takamoto M: The mode of immunopotentiating action of bestatin: enhanced resistance to Listeria Monocytogenes infection. J Antibiot (Tokyo), 1983, 36, 1411-1414. (Pubitemid 14232208)
10. Hirayama Y, Sakamaki S, Takayangi N, Tsuji Y, Sagawa T, Chiba H, Matsunaga T, Niitsu Y: Chemotherapy with ubenimex corresponding to patient age and organ disorder for 18 cases of acute myelogeneous leukemia in elderly patients-effects, complications and long-term survival. Gan To Kagaku Ryoho, 2003, 30, 1113-1118.
11. Ichinose Y, Genka K, Koike T, Kato H, Watanabe Y, Mori T, Iioka S et al., NK421 Lung Cancer Surgery Group: Randomized double-blind placebo-controlled trial of bestatin in patients with resected stage I squamous-cell lung carcinoma. J Natl Cancer Inst, 2003, 95, 605-610. (Pubitemid 36553507)
12. Ino K, Bierman PJ, Varney ML, Heimann DG, Kuszynski CA, Walker SA, Talmadge JE: Monocyte activation by an oral immunomodulator ubenimex (bestatin) in lymphoma patients following autologous bone marrow transplantation. Cancer Immunol Immunother, 1996, 43, 206-212. (Pubitemid 26426252)
13. Ishizuka M, Masuda T, Kanbayashi N, Fukasawa S, Takeuchi T, Aoyagi T, Umezawa H: Effect of bestatin on mouse immune system and experimental murine tumors. J Antibiot (Tokyo), 1980, 33, 642-652. (Pubitemid 10016619)
14. Ishizuka M, Sato J, Sugiyama Y, Takeuchi T, Umezawa H: Mitogenic effect of bestatin on lymphocytes. J Antibiot (Tokyo), 1980, 33, 653-662. (Pubitemid 10016620)
15. Iwahashi M, Tanimura H, Yamaue H, Tsunoda T, Tani M, Noguchi K, Mizobata S et al.: In vitro augmentation of cytotoxic activity of peripheral blood lymphocytes and spleen cells of cancer patients by ubenimex. Anticancer Res, 1994, 14, 1557-1562. (Pubitemid 24354206)
16. Jarstrand C, Blomgren H: Bestatin, a new immunomodulator, enhances migration and phagocytosis of human granulocytes in vitro. J Clin Lab Immunol, 1981, 5, 67-69. (Pubitemid 11146121)
17. Knoblich A, Müller WE, Harle-Grupp V, Falke D: Enhancement of antibody formation against herpes simplex virus in mice by the T-cell mitogen bestatin. J Gen Virol, 1984, 65, 1675-1686. (Pubitemid 14023668)
18. Kuramochi H, Motegi A, Iwabuchi M, Takahashi K, Horinishi H, Umezawa H: Action of ubenimex on aminopeptidase activities in spleen cells and peritoneal macrophages from mice. J Antibiot (Tokyo), 1987, 40, 1605-1611. (Pubitemid 17161593)
19. Lkhagvaa B, Tani K, Sato K, Toyoda Y, Suzuka C, Sone S: Bestatin, an inhibitor for aminopeptidases, modulates the production of cytokines and chemokines by activated monocytes and macrophages. Cytokine, 2008, 44, 386-391.
20. Look AT, Ashmun RA, Shapiro LH, Peiper SC: Human myeloid plasma membrane glycoprotein CD 13 (gp150) is identical to aminopeptidase N. J Clin Invest, 1989, 83, 1299-1307. (Pubitemid 19113045)
21. Mathé G: Bestatin, an aminopeptidase inhibitor with a multi-pharmacological function. Biomed Pharmacother, 1991, 45, 49-54.
22. Mishima Y, Terui Y, Sugimura N, Matsumoto-Mishma Y, Rokudai A, Kuniyoshi R, Hatake K: Continuous treatment of bestatin induces anti-angiogenic property in endothelial cells. Cancer Sci, 2007, 98, 364-372. (Pubitemid 46195607)
23. Nemoto K, Abe F, Karakawa K, Horinishi H, Umezawa H: Enhancement of colony formation of mouse bone marrow cells by ubenimex. J Antibiot (Tokyo), 1987, 40, 894-898. (Pubitemid 17086239)
24. Niimoto M, Hattori T: Prospective randomized controlled study on bestatin in resectable gastric cancer. Biomed Pharmacother, 1991, 45, 121-124.
25. Noma T, Klein B, Cupissol D, Yata J, Serrou B: Increased sensitivity of IL2-dependent cultured T cells and enhancement of in vitro IL-2 production by human lymphocytes treated with bestatin. Int J Immunopharmacol, 1984, 6, 87-92. (Pubitemid 14109017)
26. Okamura S, Omori F, Haga K, Baba H, Kawasaki C, Tanaka T, Sugimachi K, Niho Y: Ubenimex stimulates production of colony-stimulating factor from human peripheral mononuclear cells in vitro. Bestatin 16 ICC Proceedings, Jerusalem, Israel, 1989, June 11-16, p. 12.
27. Okura A, Ishizuka M, Takeuchi T: Effect of ubenimex on the production of murine interferon. J Antibiot (Tokyo), 1988, 41, 261-263. (Pubitemid 18059571)
28. Ota K: Review of ubenimex (Bestatin): clinical research. Biomed Pharmacother, 1991, 45, 55-60.
29. Ota K, Uzuka Y: Clinical trials of bestatin for leukemia and solid tumors. Biotherapy, 1992, 4, 205-214.
30. Pulido-Cejudo G, Conway B, Proulx P, Brown R, Izaguirre CA: Bestatin-mediated inhibition of leucine aminopeptidase may hinder HIV infection. Antiviral Res, 1997, 36, 167-177.
31. Sasaki S, Fukushima J, Hamajima K, Ishii N, Tsuji T, Xin K-Q, Mohri H, Okuda K: Adjuvant effect of Ubenimex on a DNA vaccine for HIV-1. Clin Exp Immunol, 1998, 111, 30-35. (Pubitemid 28062774)
32. Schorlemmer HU, Bosslet K, Dickneite G, Lüben G, Sedlacek HH: Studies on the mechanisms of action of the immunomodulator Bestatin in various screening test systems. Behring Inst Mitt, 1984, 74, 157-173.
33. Schorlemmer HU, Bosslet K, Sedlacek HH: Ability of the immunomodulating dipeptide bestatin to activate cytotoxic mononuclear phagocytes. Cancer Res, 1983, 43, 4148-4153. (Pubitemid 13041045)
34. Shibuya K, Chiba S, Hino M, Kitamura T, Miyagawa K, Takaku F, Miyazano K: Enhancing effect of ubenimex (bestatin) on proliferation and differentiation of hematopoietic progenitur cells, and the suppressive effect on proliferation of leukemic cell lines via peptidase regulation. Biomed Pharmacother, 1991, 45, 71-80.
35. Shibuya K, Hayashi E, Abe F, Takahashi K, Horinishi H, Ishizuka M, Takeuchi T, Umezawa H: Enhancement of interleukin 1 and interleukin 2 releases by ubenimex. J Antibiot (Tokyo), 1987, 40, 363-369. (Pubitemid 17044884)
36. Suda H, Aoyagi T, Takeuchi T, Umezawa H: Inhibition of aminopeptidase B and leucine aminopeptidase by bestatin and its stereoisomer. Arch Biochem Biophys, 1976, 177, 196-200.
37. Talmadge JE, Lenz BF, Pennington R, Long C, Phillips H, Schneider M, Tribble H: Immunomodulatory and therapeutic properties of bestatin in mice. Cancer Res, 1986, 46, 4505-4510. (Pubitemid 16046879)
38. Tsunogake S, Furusawa A, Nagashima S, Nakamura Y, Enokihara H, Shishido H: Effect of aminopeptidase inhibitors on the production of various cytokines by peripheral blood mononuclear cells and stromal cells and on stem cell factor gene expression in stromal cells: comparison of ubenimex with its stereoisomers. Int J Immunotherapy, 1994, 10, 41-47. (Pubitemid 24216018)
39. Umezawa H, Ishizuka M, Aoyagi T, Takeuchi T: Enhancement of delayed-type hypersensitivity by bestatin, an inhibitor of aminopeptidase B and leucine aminopeptidase. J Antibiot (Tokyo), 1976, 29, 857-859.